Decreased Frequency of Circulating Myelin Oligodendrocyte Glycoprotein B Lymphocytes in Patients with Relapsing-Remitting Multiple Sclerosis

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Ngono, Annie Elong ^a,b   Lepetit, Maud ^a,c   Reindl, Markus ^d   Garcia, Alexandra ^a   Guillot, Flora ^a,b   Genty, Athénaïs ^a   Chesneau, Mélanie ^a,b   Salou, Marion ^a,b   Michel, Laure ^a,c   Lefrere, Fabienne ^e   Schanda, Kathrin ^d   Imbert Marcille, Berthe Marie ^b   Degauque, Nicolas ^a,b   Nicot, Arnaud ^a,b   Brouard, Sophie ^a,b   Laplaud, David Axel ^a,b,c   Soulillou, Jean Paul ^a,b  

^a Centre National de la Recherche Scientifique   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; DOUBLE STRANDED DNA; INSULIN; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; POLYSTYRENE; RECOMBINANT PROTEIN; ANTIBODY;

ADULT; ANTIBODY TITER; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BLOOD; CELL ASSAY; CELL MIGRATION; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PHENOTYPE; PROTEIN DOMAIN; ROSETTE FORMATION; CASE CONTROL STUDY; CELL PROLIFERATION; IMMUNOLOGY;

ADULT; ANTIBODIES; APOPTOSIS; B-LYMPHOCYTES; CASE-CONTROL STUDIES; CELL PROLIFERATION; ENDOTHELIAL CELLS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN;

EID: 85042736150     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/673503     Document Type: Article

References (56)

1. C. Lucchinetti, W. Brück, J. Parisi, B. Scheithauer, M. Rodriguez, and H. Lassmann, "Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination," Annals of Neurology, vol. 47, no. 6, pp. 707-717, 2000.
2. A. Compston and A. Coles, "Multiple sclerosis," The Lancet, vol. 372, no. 9648, pp. 1502-1517, 2008.
3. B. Bahbouhi, S. Pettré, L. Berthelot et al., "T cell recognition of self-antigen presenting cells by protein transfer assay reveals a high frequency of anti-myelin T cells in multiple sclerosis,"Brain, vol. 133, no. 6, pp. 1622-1636, 2010.
4. A. Ben-Nun, H. Wekerle, and I. R. Cohen, "Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive againstmyelin basic protein," Nature, vol. 292, no. 5818, pp. 60-61, 1981.
5. H. Wekerle, "Lessons from multiple sclerosis: models, concepts, observations," Annals of the Rheumatic Diseases, vol. 67, supplement 3, pp. iii56-iii60, 2008.
6. A. G. Baxter, "The origin and application of experimental autoimmune encephalomyelitis," Nature Reviews Immunology, vol. 7, no. 11, pp. 904-912, 2007.
7. A. Elong Ngono, S. Pettré, M. Salou et al., "Frequency of circulating autoreactive T cells committed to myelin determinants in relapsing-remittingmultiple sclerosis patients," Clinical Immunology, vol. 144, no. 2, pp. 117-126, 2012.
8. M. Krumbholz, T. Derfuss, R. Hohlfeld, and E. Meinl, "B cells and antibodies in multiple sclerosis pathogenesis and therapy,"Nature Reviews Neurology, vol. 8, no. 11, pp. 613-623, 2012.
9. M. Reindl, F. Di Pauli, K. Rostásy, and T. Berger, "The spectrum of MOG autoantibody-associated demyelinating diseases,"Nature Reviews Neurology, vol. 9, no. 8, pp. 455-461, 2013.
10. S. L. Hauser, E. Waubant, D. L. Arnold et al., "B-cell depletion with rituximab in relapsing-remitting multiple sclerosis," The New England Journal of Medicine, vol. 358, no. 7, pp. 676-688, 2008.
11. E. G. Kamburova, H. J. P. M. Koenen, K. J. E. Borgman, I. J. Ten Berge, I. Joosten, and L. B. Hilbrands, "A single dose of rituximab does not deplete b cells in secondary lymphoid organs but alters phenotype and function," American Journal of Transplantation, vol. 13, no. 6, pp. 1503-1511, 2013.
12. + T-cell proliferation and IFN-γ production in response tomyelin basic protein and myelin oligodendrocyte glycoprotein," European Journal of Immunology, vol. 40, no. 10, pp. 2942-2956, 2010.
13. C. Mauri and A. Bosma, "Immune regulatory function of B cells," Annual Review of Immunology, vol. 30, pp. 221-241, 2012.
14. S. Fillatreau, C. H. Sweenie, M. J. McGeachy, D. Gray, and S. M. Anderton, "B cells regulate autoimmunity by provision of IL-10," Nature Immunology, vol. 3, no. 10, pp. 944-950, 2002.
15. L. le Texier, P. Thebault, A. Lavault et al., "Long-term allograft tolerance is characterized by the accumulation of B cells exhibiting an inhibited profile," The American Journal of Transplantation, vol. 11, no. 3, pp. 429-438, 2011.
16. M. Chesneau, A. Pallier, F. Braza et al., "Unique B cell differentiation profile in tolerant kidney transplant patients," The American Journal of Transplantation, vol. 14, no. 1, pp. 144-155, 2014.
17. S. Knippenberg, E. Peelen, J. Smolders et al., "Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naïve/memory Breg ratio during a relapse but not in remission," Journal of Neuroimmunology, vol. 239, no. 1-2, pp. 80-86, 2011.
18. Y. Iwata, T. Matsushita, M. Horikawa et al., "Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells," Blood, vol. 117, no. 2, pp. 530-541, 2011.
19. H. Wardemann, S. Yurasov, A. Schaefer, J. W. Young, E. Meffre, and M. C. Nussenzweig, "Predominant autoantibody production by early human B cell precursors," Science, vol. 301, no. 5638, pp. 1374-1377, 2003.
20. E. Meffre and H. Wardemann, "B-cell tolerance checkpoints in health and autoimmunity," Current Opinion in Immunology, vol. 20, no. 6, pp. 632-638, 2008.
21. N. Degauque, A. E. Ngono, A. Akl et al., "Characterization of antigen-specific B cells using nominal antigen-coated flow-beads,"PLoS ONE, vol. 8, no. 12, Article ID e84273, 2013.
22. K. Raddassi, S. C. Kent, J. Yang et al., "Increased frequencies of myelin oligodendrocyte glycoprotein/MHC class II-binding CD4 cells in patients with multiple sclerosis," Journal of Immunology, vol. 187, no. 2, pp. 1039-1046, 2011.
23. C. H. Polman, S. C. Reingold, G. Edan et al., "Diagnostic criteria formultiple sclerosis: 2005 revisions to the 'McDonald Criteria',"Annals of Neurology, vol. 58, no. 6, pp. 840-846, 2005.
24. C. Breithaupt, B. Schäfer, H. Pellkofer, R. Huber, C. Linington, and U. Jacob, "Demyelinating myelin oligodendrocyte glycoprotein-specific autoantibody response is focused on one dominant conformational epitope region in rodents," Journal of Immunology, vol. 181, no. 2, pp. 1255-1263, 2008.
25. B. B. Weksler, E. A. Subileau, N. Perrière et al., "Blood-brain barrier-specific properties of a human adult brain endothelial cell line," The FASEB Journal, vol. 19, no. 13, pp. 1872-1874, 2005.
26. B. Bahbouhi, L. Berthelot, S. Pettré et al., "Peripheral blood CD4+ T lymphocytes from multiple sclerosis patients are characterized by higher PSGL-1 expression and transmigration capacity across a human blood-brain barrier-derived endothelial cell line," Journal of Leukocyte Biology, vol. 86, no. 5, pp. 1049-1063, 2009.
27. F. di Pauli, S. Mader, K. Rostasy et al., "Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases," Clinical Immunology, vol. 138, no. 3, pp. 247-254, 2011.
28. T. Litzenburger, R. Fässler, J. Bauer et al., "B lymphocytes producing demyelinating autoantibodies: development and function in gene-targeted transgenic mice," Journal of Experimental Medicine, vol. 188, no. 1, pp. 169-180, 1998.
29. D.-H. Lee and R.A. Linker, "The role of myelin oligodendrocyte glycoprotein in autoimmune demyelination: a target for multiple sclerosis therapy?" Expert Opinion on Therapeutic Targets, vol. 16, no. 5, pp. 451-462, 2012.
30. I. J. Amanna, N. E. Carlson, and M. K. Slifka, "Duration of humoral immunity to common viral and vaccine antigens," The New England Journal of Medicine, vol. 357, no. 19, pp. 1903-1915, 2007.
31. + peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells," The Journal of Experimental Medicine, vol. 188, no. 9, pp. 1679-1689, 1998.
32. A. L. Peters, L. L. Stunz, and G. A. Bishop, "CD40 and autoimmunity: the dark side of a great activator," Seminars in Immunology, vol. 21, no. 5, pp. 293-300, 2009.
33. J. Gerdes, U. Schwab, H. Lemke, and H. Stein, "Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation," International Journal of Cancer, vol. 31, no. 1, pp. 13-20, 1983.
34. A. Alter, M. Duddy, S. Hebert et al., "Determinants of human B cell migration across brain endothelial cells," Journal of Immunology, vol. 170, no. 9, pp. 4497-4505, 2003.
35. R. A. Farrell, D. Antony, G. R. Wall et al., "Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI," Neurology, vol. 73, no. 1, pp. 32-38, 2009.
36. L. I. Levin, K. L. Munger, M. V. Rubertone et al., "Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis," The Journal of the American Medical Association, vol. 293, no. 20, pp. 2496-2500, 2005.
37. C. Linington, T. Berger, L. Perry et al., "T cells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system," European Journal of Immunology, vol. 23, no. 6, pp. 1364-1372, 1993.
38. N. Baumann and D. Pham-Dinh, "Biology of oligodendrocyte and myelin in the mammalian central nervous system," Physiological Reviews, vol. 81, no. 2, pp. 871-927, 2001.
39. H.-C. von Büdingen, S. L. Hauser, J.-C. Ouallet, N. Tanuma, T. Menge, andC. P. Genain, "Frontline: epitope recognition on the myelin/oligodendrocyte glycoprotein differentially influences disease phenotype and antibody effector functions in autoimmune demyelination," European Journal of Immunology, vol. 34, no. 8, pp. 2072-2083, 2004.
40. S. J. Pittock, M. Reindl, S. Achenbach et al., "Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: Frequency, stability and clinicopathologic correlations," Multiple Sclerosis Journal, vol. 13, no. 1, pp. 7-16, 2007.
41. C. A. Muniz Caldas and J. Freire de Carvalho, "The role of environmental factors in the pathogenesis of non-organ-specific autoimmune diseases," Best Practice and Research: Clinical Rheumatology, vol. 26, no. 1, pp. 5-11, 2012.
42. G. R. Persson, "Rheumatoid arthritis and periodontitis - inflammatory and infectious connections. Review of the literature,"Journal of OralMicrobiology, vol. 4, Article ID11829, 2012.
43. P. O. Barros, U. C. Linhares, B. Teixeira et al., "High in vitro immune reactivity to Escherichia coli in neuromyelitis optica patients is correlated with both neurological disabilities and elevated plasma lipopolysaccharide levels," Human Immunology, vol. 74, no. 9, pp. 1080-1087, 2013.
44. S. Ferrari-Lacraz, J.-M. Tiercy, and J. Villard, "Detection of anti-HLA antibodies by solid-phase assay in kidney transplantation: friend or foe?" Tissue Antigens, vol. 79, no. 5, pp. 315-325, 2012.
45. D. O. Griffin and T. L. Rothstein, "Human B1 cell frequency: isolation and analysis of human B1 cells," Frontiers in Immunology, vol. 3, article 122, 2012.
46. C. Tørring, C. C. Petersen, L. Bjerg, E.Kofod-Olsen, T. Petersen, and P. Höllsberg, "The B1-cell subpopulation is diminished in patients with relapsing-remitting multiple sclerosis," Journal of Neuroimmunology, vol. 262, no. 1-2, pp. 92-99, 2013.
47. T. Kinnunen, N. Chamberlain, H. Morbach et al., "Specific peripheral B cell tolerance defects in patients with multiple sclerosis," Journal of Clinical Investigation, vol. 123, no. 6, pp. 2737-2741, 2013.
48. S. Kuerten, G. Pommerschein, S. K. Barth et al., "Identification of a B cell-dependent subpopulation of multiple sclerosis by measurements of brain-reactive B cells in the blood," Clinical Immunology, vol. 152, no. 1-2, pp. 20-24, 2014.
49. M. Markovic, V. Trajkovic, J. Drulovic et al., "Antibodies against myelin oligodendrocyte glycoprotein in the cerebrospinal fluid of multiple sclerosis patients," Journal of the Neurological Sciences, vol. 211, no. 1-2, pp. 67-73, 2003.
50. H.-C. von Büdingen, T. C. Kuo, M. Sirota et al., "B cell exchange across the blood-brain barrier in multiple sclerosis," Journal of Clinical Investigation, vol. 122, no. 12, pp. 4533-4543, 2012.
51. A. Palanichamy, L. Apeltsin, T. C. Kuo et al., "Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis," Science Translational Medicine, vol. 6, no. 248, p. 248ra106, 2014.
52. B. Melchior, V. Nérrière-Daguin, N. Degauque et al., "Compartmentalization of TCR repertoire alteration during rejection of an intrabrain xenograft," Experimental Neurology, vol. 192, no. 2, pp. 373-383, 2005.
53. J. J. Iliff, M. Wang, Y. Liao et al., "A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β," Science Translational Medicine, vol. 4, no. 147, Article ID 147ra111, 2012.
54. L. Yang, B. T. Kress, H. J. Weber et al., "Evaluating glymphatic pathway function utilizing clinically relevant intrathecal infusion of CSF tracer," Journal of Translational Medicine, vol. 11, no. 1, article 107, 2013.
55. N. Molnarfi, U. Schulze-Topphoff, M. S. Weber et al., "MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies,"Journal of Experimental Medicine, vol. 210, no. 13, pp. 2921-2937, 2013.
56. P.Shen T.Roch V.Lampropoulouet alIL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseasesNature5077492366-3702014